Overview

Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

Status:
Completed
Trial end date:
2021-04-02
Target enrollment:
Participant gender:
Summary
The purpose is to assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in up to 60 Patients with Acromegaly
Phase:
Phase 2
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.
Treatments:
Somatostatin